The Experts below are selected from a list of 78 Experts worldwide ranked by ideXlab platform
Isabel Madruga - One of the best experts on this subject based on the ideXlab platform.
-
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
European journal of case reports in internal medicine, 2019Co-Authors: Ines Esteves Cruz, Pedro F. Ferreira, Raquel Assed Bezerra Da Silva, Francisco J. G. Silva, Isabel MadrugaAbstract:Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is Directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a Direct factor Xa Inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a Direct Xa Inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety. LEARNING POINTS Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT. Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, Directed towards preventing thrombosis or its recurrence. A Direct factor Xa Inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment. Keywords: Inferior vena cava agenesis, deep vein thrombosis, Direct factor Xa Inhibitors, rivaroXaban INTRODUCTION The inferior vena cava (IVC) is formed by the development, regression and anastomosis of 3 pairs of veins (posterior cardinal, subcardinal and supracardinal) between the sixth and eighth weeks of gestation. If this process is not completed in time or if intrauterine or perinatal thrombosis occurs, malformations can take place. These include a duplicated IVC, IVC agenesis or the interruption of a specific segment. Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition[1]. Imaging criteria for IVC agenesis diagnosis include absence of the IVC lumen, associated with a connection between the existent caval segment and the azygous system, and the existence of venous collaterals (paravertebral venous system and its communications with the ascending lumbar veins and azygous–hemiazygous system; gonadal, periureteral and other retroperitoneal veins; abdominal wall veins; haemorrhoidal venous plexus and the portal venous system)[2].
Ines Esteves Cruz - One of the best experts on this subject based on the ideXlab platform.
-
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
European journal of case reports in internal medicine, 2019Co-Authors: Ines Esteves Cruz, Pedro F. Ferreira, Raquel Assed Bezerra Da Silva, Francisco J. G. Silva, Isabel MadrugaAbstract:Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is Directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a Direct factor Xa Inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a Direct Xa Inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety. LEARNING POINTS Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT. Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, Directed towards preventing thrombosis or its recurrence. A Direct factor Xa Inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment. Keywords: Inferior vena cava agenesis, deep vein thrombosis, Direct factor Xa Inhibitors, rivaroXaban INTRODUCTION The inferior vena cava (IVC) is formed by the development, regression and anastomosis of 3 pairs of veins (posterior cardinal, subcardinal and supracardinal) between the sixth and eighth weeks of gestation. If this process is not completed in time or if intrauterine or perinatal thrombosis occurs, malformations can take place. These include a duplicated IVC, IVC agenesis or the interruption of a specific segment. Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition[1]. Imaging criteria for IVC agenesis diagnosis include absence of the IVC lumen, associated with a connection between the existent caval segment and the azygous system, and the existence of venous collaterals (paravertebral venous system and its communications with the ascending lumbar veins and azygous–hemiazygous system; gonadal, periureteral and other retroperitoneal veins; abdominal wall veins; haemorrhoidal venous plexus and the portal venous system)[2].
Pedro F. Ferreira - One of the best experts on this subject based on the ideXlab platform.
-
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
European journal of case reports in internal medicine, 2019Co-Authors: Ines Esteves Cruz, Pedro F. Ferreira, Raquel Assed Bezerra Da Silva, Francisco J. G. Silva, Isabel MadrugaAbstract:Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is Directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a Direct factor Xa Inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a Direct Xa Inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety. LEARNING POINTS Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT. Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, Directed towards preventing thrombosis or its recurrence. A Direct factor Xa Inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment. Keywords: Inferior vena cava agenesis, deep vein thrombosis, Direct factor Xa Inhibitors, rivaroXaban INTRODUCTION The inferior vena cava (IVC) is formed by the development, regression and anastomosis of 3 pairs of veins (posterior cardinal, subcardinal and supracardinal) between the sixth and eighth weeks of gestation. If this process is not completed in time or if intrauterine or perinatal thrombosis occurs, malformations can take place. These include a duplicated IVC, IVC agenesis or the interruption of a specific segment. Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition[1]. Imaging criteria for IVC agenesis diagnosis include absence of the IVC lumen, associated with a connection between the existent caval segment and the azygous system, and the existence of venous collaterals (paravertebral venous system and its communications with the ascending lumbar veins and azygous–hemiazygous system; gonadal, periureteral and other retroperitoneal veins; abdominal wall veins; haemorrhoidal venous plexus and the portal venous system)[2].
Francisco J. G. Silva - One of the best experts on this subject based on the ideXlab platform.
-
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
European journal of case reports in internal medicine, 2019Co-Authors: Ines Esteves Cruz, Pedro F. Ferreira, Raquel Assed Bezerra Da Silva, Francisco J. G. Silva, Isabel MadrugaAbstract:Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is Directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a Direct factor Xa Inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a Direct Xa Inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety. LEARNING POINTS Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT. Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, Directed towards preventing thrombosis or its recurrence. A Direct factor Xa Inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment. Keywords: Inferior vena cava agenesis, deep vein thrombosis, Direct factor Xa Inhibitors, rivaroXaban INTRODUCTION The inferior vena cava (IVC) is formed by the development, regression and anastomosis of 3 pairs of veins (posterior cardinal, subcardinal and supracardinal) between the sixth and eighth weeks of gestation. If this process is not completed in time or if intrauterine or perinatal thrombosis occurs, malformations can take place. These include a duplicated IVC, IVC agenesis or the interruption of a specific segment. Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition[1]. Imaging criteria for IVC agenesis diagnosis include absence of the IVC lumen, associated with a connection between the existent caval segment and the azygous system, and the existence of venous collaterals (paravertebral venous system and its communications with the ascending lumbar veins and azygous–hemiazygous system; gonadal, periureteral and other retroperitoneal veins; abdominal wall veins; haemorrhoidal venous plexus and the portal venous system)[2].
Raquel Assed Bezerra Da Silva - One of the best experts on this subject based on the ideXlab platform.
-
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
European journal of case reports in internal medicine, 2019Co-Authors: Ines Esteves Cruz, Pedro F. Ferreira, Raquel Assed Bezerra Da Silva, Francisco J. G. Silva, Isabel MadrugaAbstract:Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is Directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a Direct factor Xa Inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a Direct Xa Inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety. LEARNING POINTS Up to 5% of young individuals under 30 years of age with unprovoked deep vein thrombosis (DVT) are found to have this condition. Therefore, these types of anomalies should be actively looked for, particularly in young patients with DVT. Treatment with low molecular weight heparin or oral anticoagulation medication is the mainstay of therapy, Directed towards preventing thrombosis or its recurrence. A Direct factor Xa Inhibitor could be a possible alternative to vitamin K antagonists in these patients, despite the lack of clinical evidence supporting its use at the moment. Keywords: Inferior vena cava agenesis, deep vein thrombosis, Direct factor Xa Inhibitors, rivaroXaban INTRODUCTION The inferior vena cava (IVC) is formed by the development, regression and anastomosis of 3 pairs of veins (posterior cardinal, subcardinal and supracardinal) between the sixth and eighth weeks of gestation. If this process is not completed in time or if intrauterine or perinatal thrombosis occurs, malformations can take place. These include a duplicated IVC, IVC agenesis or the interruption of a specific segment. Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition[1]. Imaging criteria for IVC agenesis diagnosis include absence of the IVC lumen, associated with a connection between the existent caval segment and the azygous system, and the existence of venous collaterals (paravertebral venous system and its communications with the ascending lumbar veins and azygous–hemiazygous system; gonadal, periureteral and other retroperitoneal veins; abdominal wall veins; haemorrhoidal venous plexus and the portal venous system)[2].